SCHEMBL9501304

SCHEMBL9501304

CCOC(=O)c1cn(C2CC2)c2cc(F)c(F)c(N)c2c1=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 6/20 0.49
ADRB2 P07550 1/20 0.48
TOP2A P11388 1/20 0.45
TOP2B Q02880 1/20 0.45
STAT3 P40763 2/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.43
KCNH2 Q12809 2/20 0.41
CACNA1F O60840 1/20 0.41
POLB P06746 1/20 0.41
MAPK1 P28482 1/20 0.41
CACNA1D Q01668 1/20 0.41
CACNA1S Q13698 1/20 0.41
CACNA1C Q13936 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
FOXO1 Q12778 1/20 0.41
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1343013 0.93 GSK3B (0.44) GSK3BADRB2TOP2ATOP2BSTAT3
SCHEMBL9501129 0.91 ADRB2 (0.51) GSK3BADRB2TOP2ATOP2BSTAT3
SCHEMBL9265456 0.91 STAT3 (0.42) GSK3BADRB2TOP2ATOP2BSTAT3
SCHEMBL30181222 0.90 ADRB2 (0.50) GSK3BADRB2TOP2ATOP2BSTAT3
SCHEMBL5507636 0.90 ADRB2 (0.50) GSK3BADRB2TOP2ATOP2BSTAT3
SCHEMBL263981 0.87 STAT3 (0.48) GSK3BADRB2TOP2ATOP2BSTAT3
SCHEMBL1344567 0.84 HSD17B10 (0.46) GSK3BADRB2TOP2ATOP2BSTAT3
SCHEMBL9502034 0.84 KCNH2 (0.54) GSK3BADRB2TOP2ATOP2BSTAT3
SCHEMBL9502045 0.84 KCNH2 (0.54) GSK3BADRB2TOP2ATOP2BSTAT3
SCHEMBL25069771 0.83 STAT3 (0.48) STAT3HTTKMT2AFOXO1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230058189-A1 QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME Frequency Therapeutics, Inc. (US) 2023-02-23 US disclosed
EP-0312085-B1 NOVEL QUINOLINE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND ANTIBACTERIAL AGENT CONTAINING THEM Dainippon Pharmaceutical Co., Ltd. (JP) 1993-05-12 EP disclosed
US-5164392-A Active against streptococci and staphylococci DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1992-11-17 US disclosed
US-5013841-A Oxo quinoline derivatives DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 1991-05-07 US disclosed
EP-0312085-A2 Novel quinoline derivatives, processes for preparation thereof and antibacterial agent containing them Dainippon Pharmaceutical Co., Ltd. (JP) 1989-04-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230058189-A1 QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME DCX, NES, MCL1 GSK3B 1102/4885ADRB2 4044/4885TOP2A 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.